Latest news and press releases about Enlivex Therapeutics Ltd. (ENLV): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Enlivex Therapeutics Ltd., established in 2005 and based in Nes Ziona, Israel, operates as a clinical-stage biotechnology firm dedicated to macrophage reprogramming immunotherapy. The company is currently advancing Allocetra, its flagship cell-based therapeutic. This treatment is undergoing Phase II clinical evaluation for its effectiveness in addressing organ dysfunction and failure that arises from sepsis.
Price
| Price | $0.81 |
| Market Cap | $14M |
| Exchange | NASDAQ |
| Country | IL |
Valuation Ratios
| P/E Ratio | 0.00 |
| Price / Book | 0.00 |
| EV / EBITDA | -1.20 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 248.08% |
| Return on Invested Capital | -0.49% |
| Return on Assets | 53.10% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: CLGN · CVKD · GDTC · LSTA · MTVA · NCNA · NRSN
Explore sector: Healthcare · Biotechnology
More sections of ENLV: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks